Medical Writing Patient-reported outcomes The UK pharmaceutical industry braces for Brexit, be it mild, severe, or doomsday
front-cover-mew-decpng

Volume 27, Issue 4 - Patient-reported outcomes

The UK pharmaceutical industry braces for Brexit, be it mild, severe, or doomsday

Abstract

Pharma-Brexit is on its way. The announcement of the European Medicine Agency’s move to Amsterdam, various UK government white papers, and comments made by key stakeholders in the UK pharmaceutical industry have led to a wide range of predictions concerning Brexit. While many hope for a Norwegian-type situation where business as usual could continue uninterrupted, others fear that the uncertainty of a “no-deal” outcome has already started a domino effect that could lead to the UK pharmaceutical industry’s collapse. This article argues that something inbetween is most likely and looks at what Brexit could mean in each scenario. It explores why and how both the EU and UK might work through a deal and how these challenges might still provide opportunities for medical writers.

Download the full article

References

  1. PricewaterhouseCoopers. Brexit: Implications for Pharma and Life Sciences. 2018 [cited 28 August 2018]. Available from: Available from: https://www.pwc.nl/en/brexit/documents/pwc-brexit-monitor-pharma-life-sciences.pdf
  2. Charles River Associates. Assessing the impact on the life sciences industry of a change in the UK relationship with the EU. 2016 [cited 28 August 2018] Available from: Available from: https://www.efpia.eu/media/ 25053/assessing-the-impact-on-the-lifesciences- industry-of-a-change-in-the-ukrelationship- with-the-eu-june-2016.pdf.
  3. Business Insider UK. House of Lords voted for Theresa May to negotiate a Norwaystyle Brexit. 2018 [cited 04 August 2018]. Available from: Available from: http://uk.businessinsider.com/what-isthe- norway-model-brexit-2018-4.
  4. European Medical Agency Brexit plan. 2018. [cited 04 August 2018]. Available from: Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/news_and_.events/ general/general_content_001707.jsp&mid =WC0b01ac0580a809a7.
  5. European Commission Directorate- General for Health and Food Safety. Notice to Stakeholders. Withdrawal of the United Kingdom and EU rules in the field of clinical trials. Brussels 06 September 2018. Available from: http://
  6. Salako S, Embley P. Brexit: The legal and regulatory impact on supply chain and pharmacovigilance. Regulatory Rapporteur 2018;15(10):4–7. Available from: http://
  7. Morris C. Brexit: What would ‘no deal’ mean for food and medicine? BBC News 03 August 2018. [cited 20 Oct ober 2018] Available from: Available from: https://www.bbc.co.uk/ news/uk-45047874.
  8. Carr M. Britain Will Probably See Higher Risks of Blackouts After Brexit. Bloomberg 29 January 2018. [cited 16 October 2018] Available from: Available from: https://www.bloomberg.com/news/articles /2018-01-29/brexit-impact-on-energyseen- boosting-risks-of-blackouts-in-u-k.
  9. BBC News. Carney: No-deal Brexit risk ‘uncomfortably high’ 03 August 2018. [cited 16 October 2018] Available from: Available from: https://www.bbc.co.uk/news/business- 45055861.
  10. House of Commons Business, Energy and Industrial Strategy Committee. The impact of Brexit on the pharmaceutical sector: Ninth Report. 2018. [cited 28 August 2018] Available from: Available from: https://publications.parliament.uk/pa/cm 201719/cmselect/cmbeis/382/382.pdf.
  11. HM Government. The Future Relationship between the United Kingdom and the European Union. 2018 [cited 31 August 2018] Available from: Available from: https://www. gov.uk/government/publications/thefuture- relationship-between-the-unitedkingdom- and-the-european-union.
  12. Kazzazi F, Pollard C, Tern P, Ayuso-Garcia A, Gillespie J, Thomsen I. Evaluating the impact of Brexit on the pharmaceutical industry. J Pharm Policy Pract. 2017;10(1):32. Available from: http://
  13. Parliamentary Office of Science and Technology. Regulating Clinical Trials. Post note number 561, October 2017. [cited 16 October 2018] Available from: Available from: https://researchbriefings.files.parliament. uk/documents/POST-PN-0561/ POST-PN-0561.pdf.
  14. Golding B, Waring M. The consequences of ‘Brexit’ for drug discovery and development, and the regulatory implications. Expert Opin Drug Discov. 2018;13(7):583–5. Available from: http://
  15. BBC News. AstraZeneca to stockpile drugs for Brexit. 17 July 2018. [cited 28 August 2018]. Available from: Available from: Available from: https://www.bbc. co.uk/news/business-44847914.

Search

Articles

Patient reported outcomes
President's Message
EMWA News
Measuring health outcomes: The foundation of contemporary healthcare decision-making
Measuring quality of life – theoretical background
Quality of life measures – an overview
Publication planning and patient-reported outcomes: Demonstrating value in a multi-stakeholder era
Patient-reported outcome measure translation: An overview
Systematic hospital collection of patient-reported outcome data via patient apps
The PROMIS of electronic patient-reported outcomes
Interview with Professor Matthias Rose on developing patient-reported outcomes and the PROMIS initiative
The UK pharmaceutical industry braces for Brexit, be it mild, severe, or doomsday
Awareness of medical writing as a profession and its career prospects
Estimands – closing the gap between study design and analysis
Protecting the rights of clinical trial patients through disclosure: The significance of plain language
News from the EMA
Regulatory Matters & Regulatory Public Disclosure
Medical Communications
Medical Devices
Journal Watch
In the Bookstores
Good Writing Practice
Getting Your Foot In The Door
My First Medical Writing
Out on Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: